Live tape
Top 8, mentions 7d30,017NVDA14,564 mentions▲ +0.04ANT4,160 mentions▲ +0.06GOOGL2,936 mentions▲ +0.04SPY2,248 mentions▲ +0.05QQQ1,804 mentions▲ +0.04SPCX1,748 mentions▲ +0.08AMD1,367 mentions▲ +0.06AAPL1,190 mentions▲ +0.04

Equity · Healthcare

NMRA

NASDAQ

Neumora Therapeutics (NMRA)

0.7469 USD −3.01% vs prior close Sep 17, 2026
Neumora Therapeutics, Inc. price graph
18 sessions
2.0 0.5 24 Aug 17 Sep

The line runs 1.53 USD on 24 August through 0.7469 USD on 17 September, on a scale from 0.5 to 2.0. Days the market did not trade hold the previous close, flat.

Market cap
140.9M USD
EPS, diluted, year to Dec 2025
−1.45 USD
Avg volume
98.2K

as of Sep 17, 2026

Have Neumora Therapeutics (NMRA) insiders bought or sold shares recently?

NMRA's newest Form 4 filing is dated 21 August 2026: none in the last 90 days.

Form 4

Have Neumora Therapeutics (NMRA) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
21 Aug 2026Aurora Daljit SinghSee RemarksSell41,60866K USD
20 Aug 2026Aurora Daljit SinghSee RemarksSell134,452204K USD
19 Aug 2026Aurora Daljit SinghSee RemarksSell61,918102K USD
18 Aug 2026Aurora Daljit SinghSee RemarksSell69,149110K USD
17 Aug 2026Aurora Daljit SinghSee RemarksSell146,706220K USD
17 Feb 2026Aurora Daljit SinghSee RemarksSell6,16522K USD
17 Feb 2026BERNS PAUL LSee RemarksSell9,81934K USD
17 Feb 2026Milligan Michael LeeSee RemarksSell1,4365K USD
17 Feb 2026Pinto JoshuaPresidentSell5,96721K USD
11 Nov 2025Aurora Daljit SinghSee RemarksSell114,703307K USD
27 Oct 2025ARCH Venture Partners XII, LLCBuy1,915,7005.0M USD
27 Oct 2025ARCH Venture Partners X, LLCBuy1,915,7005.0M USD
Bought3 open-market purchases5,747,100$15.00M
Sold10 open-market sales591,923$1.09M

Showing the 12 most recent of 13 open-market trades in this window. The figures above count all of them.

5 other filings: grants, exercises, tax withholding and transfers, not trades
Have Neumora Therapeutics (NMRA) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
21 Aug 2026Aurora Daljit SinghSee RemarksOption exercise41,60830K USD
20 Aug 2026Aurora Daljit SinghSee RemarksOption exercise134,45297K USD
19 Aug 2026Aurora Daljit SinghSee RemarksOption exercise61,91845K USD
18 Aug 2026Aurora Daljit SinghSee RemarksOption exercise69,14950K USD
17 Aug 2026Aurora Daljit SinghSee RemarksOption exercise112,68681K USD

Which funds hold Neumora Therapeutics (NMRA)?

7 of the 45 institutional funds we track reported a Neumora Therapeutics position for the quarter ended 30 Sep 2026 — a combined 4.7M USD; the latest of those filings landed 16 Nov 2026.

Form 13F

Which funds hold Neumora Therapeutics (NMRA)?
FundPositionSharesValueShares q/q
AQR Capital ManagementAdded3,062,8461.8M USD+22,399.4%
Two Sigma InvestmentsTrimmed1,390,429829K USD−38.1%
Renaissance TechnologiesHeld (±25%)1,129,735674K USD−10.5%
Citadel AdvisorsHeld (±25%)1,027,951613K USD+24.0%
Tudor Investment CorpTrimmed631,091376K USD−53.5%
Marshall WaceTrimmed330,514198K USD−63.5%
Millennium ManagementTrimmed328,544196K USD−35.5%

What has been filed or recorded for Neumora Therapeutics (NMRA)?

The filings we hold for Neumora Therapeutics, newest first: 3 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 16 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Neumora Therapeutics (NMRA)?
And
16 Oct 2026Fails to deliverShares failed to deliver88,883 shares38K USD notional · 0.047% of shares out
13 Oct 2026Fails to deliverShares failed to deliver429 shares189 USD notional · <0.001% of shares out
07 Oct 2026Fails to deliverShares failed to deliver67,361 shares32K USD notional · 0.036% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.18 USD
30 Sep 2026FinancialsTotal assets95.0M USDat period end
30 Sep 2026FinancialsTotal equity18.6M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.23 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.30 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −1.45 USD
31 Dec 2025FinancialsNet income−236.9M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−1.45 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.35 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.33 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.42 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −1.53 USD

What do people ask about Neumora Therapeutics (NMRA)?

From live data
What did Neumora Therapeutics shares close at?0.7469

Neumora Therapeutics closed at 0.7469 USD on 17 Sep 2026, down 3.01% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Neumora Therapeutics’ market cap?140.9M

Neumora Therapeutics is worth 140.9M USD by market value as of 17 Sep 2026, which is the share price times the shares on issue from its SEC filings.

Have Neumora Therapeutics insiders bought or sold shares recently?

No Neumora Therapeutics insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 21 Aug 2026 (SEC Form 4). See Insiders

Which funds own Neumora Therapeutics?7 of 45

7 of the 45 funds we track reported a Neumora Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were AQR Capital Management, Two Sigma Investments and Renaissance Technologies. See Funds

When did Neumora Therapeutics last report earnings?−0.18

Neumora Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.18 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings
  9. SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words